Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Net Income	-210.96	-156.73	-107.43	-66.39	-28.6
Depreciation & Amortization	1.32	1.23	1	0.02	0.01
Share-Based Compensation	32.3	34.24	18.82	6.96	1.31
Other Operating Activities	-10.85	15.14	4.28	6.05	-1.27
Operating Cash Flow	-188.19	-106.11	-83.33	-53.36	-28.55
Capital Expenditures	-0.2	-0.25	-0.21	-0.03	-0.05
Investing Cash Flow	-0.2	-0.25	-0.21	-0.03	-0.05
Share Issuance / Repurchase	71.16	0.13	387.54	1.16	31.04
Debt Issued / Paid	0	0	-3.19	37.91	0
Other Financing Activities	-0.27	200	-1.24	107.91	4.54
Financing Cash Flow	70.89	200.13	383.11	146.97	35.58
Exchange Rate Effect	0.22	-0.09	0	0	0
Net Cash Flow	-117.29	93.67	299.58	93.59	6.99
Free Cash Flow	-188.39	-106.37	-83.54	-53.39	-28.6
Free Cash Flow Per Share	-1.53	-0.97	-0.95	-1.24	-1.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).